-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
For a long time, patients with activated B-cell-like (ABC) subtypes of diffuse large B-cell lymphoma (DLBCL) have been treated with rituximab + cyclophosphamide + adriamycin + vincristine and prednisone (R- The prognosis of survival under standard treatment of CHOP is poor.
Lymphoma immunity
The ROBUST study is a global phase III clinical adaptation that aims to compare the efficacy of R-CHOP combined with lenalidomide or placebo in patients with previously untreated ABC DLBCL.
To compare the efficacy of R-CHOP combined with lenalidomide or placebo in patients with previously untreated ABC DLBCL.
Before randomization and research treatment, the histology and cell types of origin were prospectively analyzed through central pathology.
A total of 570 ABC-DLBCL patients were recruited.
Adverse events
Adverse eventsMost patients completed 6 courses of treatment: 74% in the R2-CHOP group and 84% in the placebo/R-CHOP group.
Most patients completed 6 courses of treatment: 74% in the R2-CHOP group and 84% in the placebo/R-CHOP group.
PFS, EFS and OS in the intent-to-treat population
PFS, EFS and OS in the intent-to-treat populationThe primary endpoint PFS was not reached, and the median PFS of both groups was not reached, and the hazard ratio was 0.
The primary endpoint PFS was not reached, the median PFS of the two groups was not reached, and the hazard ratio was 0.
Although the ROBUST trial did not reach the primary endpoint of PFS in all patients, the safety of R2-CHOP is consistent with that of single treatment, and there are no new safety issues.
Original source:
Nowakowski Grzegorz S, Chiappella Annalisa, Gascoyne Randy D et al.
org/doi/full/10.
1200/JCO.
20.
01366" target="_blank" rel="noopener">ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma in this message
